
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. has demonstrated strong financial performance in the second quarter of 2025, with a gross margin increase of approximately 80 basis points year-over-year, reaching 79.8%. The company also reported a significant revenue growth of around 23% year-over-year, totaling $46.4 million, indicating strong demand for its medical devices. Additionally, the increase in surgeon utilization, up roughly 25% year-over-year, further highlights the effectiveness of its sales strategy and the growing acceptance of its proprietary surgical implant systems.
Bears say
The analysis of SI-BONE Inc. indicates several fundamental challenges impacting its stock outlook. The global spine market has recently faced pricing pressures and procedural headwinds, resulting in slowed growth to low single digits, which could hinder SI-BONE's expansion prospects. Furthermore, the potential for payors to favor competitive products for reimbursement threatens to erode SI-BONE's market share in the sacroiliac joint fusion area, significantly affecting the company’s revenue potential amid an expected continuation of market headwinds.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares